ClinicalTrials.gg
CompletedNCT04810598Updated Sep 16, 2022

Study to Assess Adverse Events and the Movement of Oral Venetoclax Tablet Through the Body of Female Participants Aged 18-75 Years With Impaired Renal Function

A Phase 1 interventional study of Venetoclax in Renal Impairment and Renal Disease, sponsored by AbbVie. Completed at 2 sites in United States. Open to female participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-09-16.

Sponsored by AbbVie · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Aug 2022, 4 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Renal Insufficiency by AbbVie — none open to participants now, none under way, none of them phase 3. Renal Insufficiency · AbbVie.

Started
2021
the only one that year
Phase 1
4 of 11
none open now
Registered
9th of 11
by date

Among the 11 studies in Renal Insufficiency by AbbVie, this one is the only one that started in 2021, is one of 4 in phase 1, and was the 9th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

None of the 11 studies in Renal Insufficiency by AbbVie is open now. The open studies under Renal Insufficiency, anywhere →

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 75 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Renal Insufficiency by AbbVie as a file.
02

Study summary

Renal insufficiency is common in participants with blood cancers. The main objective of this study is to evaluate adverse events and movement of oral venetoclax tablets through the body of female participants with severe normal renal function and those with end stage renal disease (ESRD) requiring hemodialysis.

Venetoclax is an investigational drug being developed for the treatment of various hematologic malignancies. Study doctors put the participants in 1 of 2 groups, called treatment arms. Each group receives a different treatment. Approximately 12 female participants between 18 and 75 years, with Body Mass Index (BMI) between 18 to 42 kg/m2 will be enrolled in approximately 4 sites across the world.

Participants with normal renal function will receive single dose of oral venetoclax tablet. Participants with ESRD will receive oral venetoclax tablets just prior to hemodialysis (Period 1 Day 1) and between dialysis days (Period 2 Day 1), doses in the two periods will be separated by at least 7 days.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood and urine tests, checking for side effects.

03

Conditions studied

  • Renal Impairment
  • Renal Disease

Keywords

  • Renal Impairment
  • Renal Disease
  • End stage renal disease (ESRD)
  • Venetoclax
  • Venclexta
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) between 18.0 and 42.0 kg/m2.
  • or permanently surgically sterile (bilateral oophorectomy, bilateral salpingectomy, or hysterectomy).
  • Women of , practicing at least 2 protocol specified methods of that are effective from at least 30 days before starting study drug through at least 30 days after the last dose of any study drug.
  • Group 1 only: Must be in general good health based upon the results of a medical history, physical examination, and 12-lead (ECG) with normal (GFR) at Screening.
  • Group 2 only: Stable condition and acceptable for study participation based upon the results of a medical history, physical examination, laboratory profile, and ECG. Participant with end stage renal disease (ESRD) requiring dialysis on hemodialysis must have been receiving hemodialysis for at least 1 month.

Exclusion criteria

Exclusion Criteria:

  • Participants on a strict vegetarian or vegan diet.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Group 1: Participants With Normal Renal Function

    Participants with normal renal function will receive single dose of venetoclax on Day 1.

    Drug: Venetoclax

  • Experimental
    Group 2: Participants With End Stage Renal Disease

    Participants with end stage renal disease (ESRD) will receive single dose of venetoclax on Period 1 Day 1 and Period 2 Day 1 (Each period is 3 days separated by 7-day washout period).

    Drug: Venetoclax

Interventions

  • Oral Tablet

    Also known as: Venclexta, ABT-199, GDC-0199

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Adverse Events (AEs)

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above.

    Time frame: Up to approximately 38 days

  2. Maximum Plasma Concentration (Cmax) of Venetoclax (Groups 1,2)

    Maximum Plasma Concentration (Cmax) of Venetoclax.

    Time frame: Up to Day 6

  3. Time to Cmax (Tmax) of Venetoclax (Groups 1,2)

    Time to Cmax (Tmax) of Venetoclax.

    Time frame: Up to Day 6

  4. Area Under the Plasma Concentration-time Curve over time from time 0 to 48 hours (AUC0-48) of Venetoclax (Groups 1,2)

    Area Under the Plasma Concentration-time Curve over time from time 0 to 48 hours (AUC0-48).

    Time frame: Up to Day 6

  5. Pre-dose Unbound Fraction (fu) of Venetoclax in Plasma (Groups 1,2)

    Unbound Fraction (fu) of Venetoclax in Plasma.

    Time frame: Day 1

  6. Dialysis Clearance (CLdialysis) (Group 2)

    Dialysis Clearance (CLdialysis) is calculated in participants undergoing hemodialysis in Period 1.

    Time frame: Day 1

  7. Unbound Fraction Pre-dialysis (fu,predialysis) of Venetoclax in Plasma (Group 2)

    Unbound fraction pre-dialysis (fu,predialysis) of venetoclax in plasma is calculated in participants undergoing hemodialysis in Period 1.

    Time frame: Day 1

  8. Unbound Fraction Post-dialysis (fu,postdialysis) of Venetoclax in Plasma (Group 2)

    Unbound fraction post-dialysis (fu,postdialysis) of venetoclax in plasma is calculated in participants undergoing hemodialysis in Period 1.

    Time frame: Day 1

07

Study locations

2 sites
  • Orlando Clinical Research Ctr /ID# 224922
    Orlando, Florida 32809, United States
  • Acpru /Id# 243398
    Grayslake, Illinois 60030, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Aug 2022, 13 months.

Of 213 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 13 months is above that.

Counting every sponsor, half of 231 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2021
First posted
Mar 23, 2021
StartActual
Jul 8, 2021
Primary completionActual
Aug 16, 2022
CompletionActual
Aug 16, 2022
Last update
Sep 16, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04810598
Lead sponsor
AbbVie
Collaborators
Roche-Genentech
Responsible party
Sponsor
First posted
Mar 23, 2021
Start date
Jul 8, 2021
Primary completion
Aug 16, 2022
Completion
Aug 16, 2022
Last update
Sep 16, 2022

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Venetoclax

Start the discussion